LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

2018: First CAR T cell therapy approved in the US for adult patients with DLBCL and amongst the first approved in Europe

16/06/2021

Nominated by: Kite (a Gilead Company)   

Organisations in nomination: Kite (a Gilead Company)

Non-Hodgkin lymphoma (NHL) can occur at any age, and accounts for an estimated 510,000 new cases and 248,724 deaths worldwide every year. Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive form of NHL. DLBCL patients for whom two lines of therapy have failed face limited treatments options and a poor prognosis.

Chimeric Antigen Receptor (CAR) T cell therapy is an individualised treatment that uses the patient’s own immune system. After the patient’s ‘T cells’ are extracted from their blood, they are processed so that when they are infused back into the patient they can recognise and more effectively target the patient’s cancer cells. As such, CAR T therapy is tailor made for each patient and intended to be administered as a single one-off infusion.

Kite’s CAR T cell therapy received priority review status by the FDA in May 2017 and became the first CAR T therapy approved by the FDA for adults with advanced large B-cell lymphoma in October 2017. It was subsequently approved by the European Commission in August 2018.

Manufacture of CAR T therapeutics is growing in Europe, with Kite’s investment in an advanced manufacturing facility near Amsterdam indicating the complex and specialised development and supply process behind such novel therapeutic interventions.

Given its potential, CAR T cell therapy has been referred to as a “game changer in cancer treatment” and there is currently a rapidly expanding pipeline of research which aims to expand the use of CAR T across different types of cancers.

References
i American Cancer Society, Key Statistics for Non-Hodgkin Lymphoma
ii Adalberto Miranda‑Filho et al, Global patterns and trends in the incidence of non-Hodgkin lymphoma
iii Almåsbak H, Aarvak T, Vemuri MC. CAR T Cell Therapy: A Game Changer in Cancer Treatment. J Immunol Res. 2016;2016:5474602. doi:10.1155/2016/5474602
iv Jia Xin Yu et al. The global pipeline of cell therapies for cancer, Nature Reviews Drug Discovery. 2019;18(11):821‑822.
v Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood). 2015;240(8):1087–1098. doi:10.1177/1535370215584936

 

Back to the list.

Share
Alexandra Simionca
Alexandra Simionca
EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.